IRF8 and cancer: Because IRF8 is often silenced in tumor cells and MDSCs, it appears that tumor cells and MDSCs use silencing IRF8 as a mechanism to induce OPN expression to suppress T cell activation to promote tumor progression, which provides a strong rationale for neutralizing OPN in cancer patients to suppress tumor immune escape [202,203,205,206].